Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition
01:32pm, Friday, 31'st Jul 2026
Biotechnology firm Tiziana Life Sciences Ltd. (NASDAQ:TLSA) on Friday revealed promising quantitative PET imaging results from the third patient participating in its Phase 2 clinical trial.
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient
08:56am, Friday, 31'st Jul 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal fo
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
07:00am, Friday, 31'st Jul 2026
BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient
04:55am, Friday, 31'st Jul 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its...
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
07:00am, Wednesday, 22'nd Jul 2026
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies w
Qualcomm raises long-term targets as analysts highlight data center, edge AI opportunities
11:31am, Thursday, 25'th Jun 2026
Qualcomm Inc (NASDAQ:QCOM, XETRA:QCI) outlined higher long-term revenue and earnings targets at its investor day, prompting analysts at Bank of America and...
Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial
09:06am, Thursday, 25'th Jun 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has received a first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Mul
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
07:00am, Thursday, 25'th Jun 2026
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Pro
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
07:00am, Monday, 15'th Jun 2026
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies w
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
07:00am, Thursday, 28'th May 2026
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-C
Tiziana Life Sciences to present clinical updates at Jefferies healthcare conference
06:07am, Thursday, 28'th May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026. CEO Ivor Elrifi and...
FedEx sum-of-the-parts valuation points to upside as freight spin-off approaches, UBS says
06:32am, Monday, 25'th May 2026
UBS is sticking with a Buy rating on FedEx Corp (NYSE:FDX, XETRA:FDX) and a price target of $445, as the company gets ready to spin off its freight business...
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
05:06pm, Friday, 22'nd May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple sclerosis (SPMS), while also reporting expanded a
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
12:48pm, Friday, 22'nd May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple...
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
11:47am, Thursday, 21'st May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progress
